Macrolide antibiotics for treatment of asthma in adults: A meta-analysis of 18 randomized controlled clinical studies

Pulmonary Pharmacology and Therapeutics

Volumn 31, Issue , 2015, Pages 99-108

  Tong, Xiang ^a   Guo, Tingting ^b   Liu, Sitong ^a   Peng, Shifeng ^a   Yan, Zhipeng ^a   Yang, Xin ^a   Zhang, Yonggang ^a   Fan, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Asthma; Lung function; Macrolide; Meta analysis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; AIRWAY HYPER RESPONSIVENESS; ARTICLE; ASIAN; ASTHMA; CAUCASIAN; CELL COUNT; CNKI DATABASE; EMBASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MEDLINE; META ANALYSIS; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; SPUTUM; SYSTEMATIC REVIEW; WANFANG DATABASE; BRONCHUS HYPERREACTIVITY; EOSINOPHIL; IMMUNOLOGY; METABOLISM; NEUTROPHIL;

ANTI-BACTERIAL AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; EOSINOPHILS; FORCED EXPIRATORY VOLUME; HUMANS; MACROLIDES; NEUTROPHILS; PEAK EXPIRATORY FLOW RATE; SPUTUM;

EID: 84926407544     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.09.005     Document Type: Article

References (47)

1. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372:1107-1119.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. http://www.ginasthma.org/.
3. Masoli M, Denise F, Holt S, Beasley R. The Global Burden of Asthma Report. /. http://www.ginasthma.org.
4. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell D., et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
5. Tamaoki J., Kadota J., Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med Suppl 2004, 117:5-11.
6. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18:125-131.
7. Basyigit I., Yildiz F., Ozkara S.K., Yildirim E., Boyaci H., Ilgazli A. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004, 38:1400-1405.
8. Banerjee D., Honeybourne D., Khair O.A. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD. Treat Respir Med 2004, 3:59-65.
9. Koh Y., Lee M., Sun Y., Sung K., Chae J. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10:994-999.
10. Tsang K., Ho P.I., Chan K.N., Ip M.S.M., Lam W.K., Ho C.S., et al. Apilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.
11. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
12. Simpson J.L., Powell H., Boyle M.J., Scott R.J., Gibson P.G. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
13. Kostadima E., Tsiodras S., Alexopoulos E.I., Kaditis A.G., Mavrou I., Georgatou N., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004, 23:714-717.
14. Cameron E.J., Chaudhuri R., Mair F., McSharry C., Greenlaw N., Weir C.J., et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J 2013, 42:1412-1415.
15. Shoji T., Yoshida S., Sakamoto H., Hasegawa H., Nakagawa H., Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999, 29:950-956.
16. Hahn D.L., Grasmick M., Hetzel S., Yale S. Azithromycin for bronchial asthma in adults: an effectiveness trial. JAm Board. Fam Med 2012, 25:442-459.
17. Brusselle G.G., VanderStichele C., Jordens P., Deman R., Slabbynck H., Ringoet V., et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013, 68:322-329.
18. Amayasu H., Yoshida S., Ebana S., Yamamoto Y., Nishikawa T., Shoji T., et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000, 84:594-598.
19. Kraft M., Cassell G.H., Pak J., Martin R.J. Mycoplasma pneumoniae and chlamydia pneumoniae in asthmaeffect of clarithromycin. Chest 2002, 121:1782-1788.
20. Hahn D.L., Plane M.B., Mahdi O.S., Byrne G.I. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006, 1:e11.
21. Sutherland E., King T.S., Icitovic N., Sutherland E., King T.S., Icitovic N., et al. Atrial of clarithromycin for the treatment of suboptimally controlled asthma. JAllergy Clin Immunol 2010, 126:747-753.
22. Black P.N., Blasi F., Jenkins C.R., Scicchitano R., Mills G.D., Rubinfeld A.R., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001, 164:536-541.
23. He J., Zhu N., Chen X.D. Clinical impacts of azithromycin on lung function and cytokines for athmatic patients (Chinese). Fudan Univ J Med Sci 2009, 36:719-722.
24. Wang Y., Zhang S.L., Qu Y. Effect of clarithromycin on Non-eosinophilic refractory asthma (Chinese). JClin Pulm Med 2012, 17:1948-1951.
25. Xiao K.A. The study on effect of roxithromycin combined with budesonidein threpy in patients with asthma (Chinese). Guide China Med 2013, 11:119-120.
26. Yan X.Q., Wu L.Q., Lin J., Xiao X.D., Dai Y.R. Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma (Chinese). Chin J Phaacol. Ther 2008, 13:184-187.
27. Zhang L.Y., Qian Q. Clinical effect of azithromycin combined with Seretide for asthma (Chinese). Strait Pharm J 2013, 25:159-160.
28. Wang T., Pei F.Y., Song X.P., Wang Q. Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide ;concentration in bronchial asthma (Chinese). Med Innovation China 2014, 11:122-124.
29. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from invitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012, 68:479-503.
30. Bartlett J.G., Breiman R.F., Mandell L.A., File T.M. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998, 26:811-838.
31. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31:347-382.
32. Jain R., Danziger L. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004, 10:3045-3053.
33. Čulić O., Eraković V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429:209-229.
34. Bahadori K., Doyle-Waters M.M., Marra C., Lynd L., Alasaly K., Swiston J., et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24.
35. Akinbami L.J., Moorman J.E., Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. Natl Health Stat Rep 2011, 12:1-14.
36. Richeldi L., Ferrara G., Fabbri L., Lasserson T.J., Gibson P.G. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005, 3:CD002997.
37. Reiter J., Demirel N., Mendy A., Gasana J., Vieira E.R., Colin A.A., et al. Macrolides for the long-term management of asthma: a meta-analysis of randomized clinical trials. Allergy 2013, 68:1040-1049.
38. Yano T., Ichikawa Y., Komatu S., Arai S., Oizumi K. Association of mycoplasma pneumoniae antigen with initial onset of bronchial asthma. Am J Respir Crit Care Med 1994, 149:1348-1353.
39. Lieberman D., Lieberman D., Printz S., Ben-Yaakov M., Lazarovich Z., Ohana B., et al. Atypical pathogen infection in adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med 2003, 167:406-410.
40. Daian C.M., Wolff A.H., Bielory L. The role of atypical organisms in asthma. Allergy Asthma Proc 2000, 21:107-111.
41. Sabato A.R., Martin A.J., Marmion B.P., Cooper D.M. Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function. Arch Dis Child 1984, 59:1034-1037.
42. Chu H.W., Honour J.M., Rawlinson C.A., Harbeck R.J., Martin R.J. Effects of respiratory mycoplasma pneumoniae infection on allergeninduced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 2003, 71:1520-1526.
43. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
44. Spears M., Donnelly I., Jolly L., Brannigan M., Ito K., McSharry C., et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009, 33:1010-1017.
45. Reisz G., Pingleton S.K., Melethil S., Ryan P.B. The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. Am Rev Respir Dis 1983, 127:581-584.
46. Weinberger M., Hudgel D., Spector S., Chidsey C. Inhibition of theophylline clearance by troleandomycin. JAllergy Clin Immunol 1977, 59:228-231.
47. Paulsen O., Höglund P., Nilsson L.-G., Bengtsson H.-I. The interaction of erythromycin with theophylline. Eur J Clin Pharmacol 1987, 32:493-498.